Compare Novartis with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs CADILA HEALTHCARE - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS CADILA HEALTHCARE NOVARTIS/
CADILA HEALTHCARE
 
P/E (TTM) x 486.4 14.7 3,308.1% View Chart
P/BV x 28.2 2.9 983.3% View Chart
Dividend Yield % 1.6 1.4 113.5%  

Financials

 NOVARTIS   CADILA HEALTHCARE
EQUITY SHARE DATA
    NOVARTIS
Mar-18
CADILA HEALTHCARE
Mar-18
NOVARTIS/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs758558 135.8%   
Low Rs579362 160.2%   
Sales per share (Unadj.) Rs228.4116.3 196.4%  
Earnings per share (Unadj.) Rs31.717.9 177.6%  
Cash flow per share (Unadj.) Rs32.823.1 141.6%  
Dividends per share (Unadj.) Rs10.003.50 285.7%  
Dividend yield (eoy) %1.50.8 196.5%  
Book value per share (Unadj.) Rs297.185.4 347.9%  
Shares outstanding (eoy) m24.691,023.74 2.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.94.0 74.0%   
Avg P/E ratio x21.125.7 81.9%  
P/CF ratio (eoy) x20.419.9 102.7%  
Price / Book Value ratio x2.25.4 41.8%  
Dividend payout %31.519.6 160.9%   
Avg Mkt Cap Rs m16,505470,664 3.5%   
No. of employees `0000.711.8 5.7%   
Total wages/salary Rs m1,44518,545 7.8%   
Avg. sales/employee Rs Th8,441.310,072.7 83.8%   
Avg. wages/employee Rs Th2,163.61,569.1 137.9%   
Avg. net profit/employee Rs Th1,173.11,547.7 75.8%   
INCOME DATA
Net Sales Rs m5,639119,049 4.7%  
Other income Rs m1,7181,132 151.8%   
Total revenues Rs m7,357120,181 6.1%   
Gross profit Rs m-6328,475 -0.2%  
Depreciation Rs m255,388 0.5%   
Interest Rs m55911 6.1%   
Profit before tax Rs m1,57523,308 6.8%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7925,644 14.0%   
Profit after tax Rs m78418,292 4.3%  
Gross profit margin %-1.123.9 -4.6%  
Effective tax rate %50.324.2 207.5%   
Net profit margin %13.915.4 90.4%  
BALANCE SHEET DATA
Current assets Rs m9,52282,005 11.6%   
Current liabilities Rs m3,29660,720 5.4%   
Net working cap to sales %110.417.9 617.5%  
Current ratio x2.91.4 213.9%  
Inventory Days Days3773 50.1%  
Debtors Days Days2898 28.9%  
Net fixed assets Rs m4683,703 0.1%   
Share capital Rs m1231,024 12.1%   
"Free" reserves Rs m7,21386,421 8.3%   
Net worth Rs m7,33687,445 8.4%   
Long term debt Rs m025,551 0.0%   
Total assets Rs m11,105180,653 6.1%  
Interest coverage x29.526.6 110.9%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.50.7 77.1%   
Return on assets %7.610.6 71.1%  
Return on equity %10.720.9 51.1%  
Return on capital %22.222.0 101.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6142,683 0.1%   
Fx outflow Rs m3,63011,242 32.3%   
Net fx Rs m-3,57031,441 -11.4%   
CASH FLOW
From Operations Rs m1,6109,193 17.5%  
From Investments Rs m687-9,737 -7.1%  
From Financial Activity Rs m-2,677515 -519.7%  
Net Cashflow Rs m-380-29 1,309.0%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 8.3 24.1%  
FIIs % 1.6 5.9 27.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 11.0 195.5%  
Shareholders   41,647 44,069 94.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   SUVEN LIFESCIENCES  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SHASUN PHARMA  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Oct 22, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - PFIZER COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS